https://european-biotechnology.net/wp-content/uploads/2025/08/1656937470420-e1755587656527.jpg
451
800
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-08-19 07:15:482025-08-19 07:15:48BioMed X and Novo Nordisk collaborate to optimise oral peptide therapeutics
https://european-biotechnology.net/wp-content/uploads/2025/08/Lab-31-e1755511169870-1030x580-1.png
580
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-08-18 10:02:342025-08-18 10:02:34Anocca raises €38.4m to advance TCR-T leads vs. pancreatic cancer
https://european-biotechnology.net/wp-content/uploads/2025/08/EdiMembre-e1755672266386.png
468
831
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-08-18 06:53:512025-08-18 06:53:51Merck and mantro enter the foodtech market
https://european-biotechnology.net/wp-content/uploads/2025/08/Trump-tariff-delay_1505204883_D72asNd8o0A5y4JqjkwMtCYr3VYkAneC-e1755256098493.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-08-15 11:09:052025-08-15 11:09:05Trump delays 250% tariffs on non-U.S. pharmaceuticals
https://european-biotechnology.net/wp-content/uploads/2025/08/nanocelltx-1030x361-1.png
361
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-08-15 07:46:352025-08-15 07:46:35CPTx and NanoCell Therapeutics secure Eurostars grant to develop non-viral in-vivo CAR-T therapies
https://european-biotechnology.net/wp-content/uploads/2025/08/Pilatus-1030x658-1.jpg
658
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-08-14 08:52:072025-08-14 08:52:07Pilatus Biosciences Enters Clinical Collaboration with Roche
https://european-biotechnology.net/wp-content/uploads/2025/08/Kumquat-Biosciences-KRAS-Pipeline-e1755010297236.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-08-12 12:12:342025-08-12 17:02:07Bayer announces US$1.3bn oncology deal with Kumquat Biosciences
https://european-biotechnology.net/wp-content/uploads/2025/08/IO-Biotech-ASCO-2025-Cover-Image-e1754920785505-1030x581-1.jpg
581
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-08-11 14:00:262025-08-11 19:02:02IO Biotech’s cancer jab falls short in Phase 3, but Danish firm still eyes FDA approval
https://european-biotechnology.net/wp-content/uploads/2025/08/Sjogren_299197059_WsWLZnxjXMUE99D71yM8cyJKcI6Cbogx-e1755009904943.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-08-10 08:34:162025-08-10 08:34:16Novartis’ Ianalumab achieves Phase III endpoint in Sjögren’s syndrome
https://european-biotechnology.net/wp-content/uploads/2025/08/Dewpoint-1030x418-1.webp
418
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-08-08 07:19:142025-08-08 07:19:14Dewpoint Therapeutics cuts workforce, refocuses pipeline
Scroll to top
